Targeting the chemokine network in atherosclerosis

Area of Science:

• Immunology
• Cardiovascular Biology
• Molecular Medicine

Background:

• Chemokines and their receptors are crucial regulators of leukocyte trafficking and immune responses.
• Dysregulation of chemokine networks contributes to various pathologies, including atherosclerosis, a chronic inflammatory condition.
• Atherosclerosis, a leading cause of cardiovascular diseases (CVD), involves complex inflammatory processes driven by chemokines.

Purpose of the Study:

• To review recent advances in understanding the role of chemokines and their receptors in atherosclerosis.
• To explore chemokine-based biomarkers for atherosclerosis detection and monitoring.
• To highlight ongoing clinical trials targeting chemokine pathways for atherosclerosis treatment.

Main Methods:

• Literature review of recent scientific publications on chemokines, chemokine receptors, and atherosclerosis.
• Analysis of studies investigating chemokine involvement in different stages of atherosclerotic plaque development.
• Examination of human studies on chemokine-based biomarkers (biochemical, imaging, genetic) and clinical trials.

Main Results:

• Chemokines and their receptors are implicated in nearly all stages of atherosclerosis, from initial fatty streak formation to advanced plaque development.
• Various chemokine-based biomarkers show potential for diagnosing and monitoring atherosclerosis.
• Several clinical trials are investigating chemokine-targeted therapies for atherosclerosis.

Conclusions:

• Chemokines and their receptors are critical mediators of atherosclerosis and represent promising therapeutic targets.
• Chemokine-based biomarkers offer potential for improved diagnostics and prognostics in cardiovascular diseases.
• Targeting chemokine pathways holds significant therapeutic promise for managing atherosclerosis and its complications.